INCB053914 + INCB050465

INCB053914 + INCB050465 is an investigational combination of two oral small molecule inhibitors developed for oncology indications. INCB053914 is a potent, selective, and orally bioavailable pan-PIM kinase inhibitor that targets PIM1, PIM2, and PIM3 serine/threonine kinases, while INCB050465 (parsaclisib) is a highly selective and potent PI3K delta (phosphoinositide 3-kinase delta) inhibitor. Together, these agents synergistically inhibit tumor proliferation and survival pathways that are critical in hematologic malignancies, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML), by targeting interconnected signaling networks, notably the PIM kinase and PI3K/AKT/mTOR pathways.